143 related articles for article (PubMed ID: 10437645)
1. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis.
Orem A; Cimşit G; Değer O; Orem C; Vanizor B
Clin Chim Acta; 1999 Jun; 284(1):81-8. PubMed ID: 10437645
[TBL] [Abstract][Full Text] [Related]
2. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Orem C; Orem A; Uydu HA; Celik S; Erdöl C; Kural BV
Coron Artery Dis; 2002 Feb; 13(1):65-71. PubMed ID: 11917201
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M
Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis.
Vanizor Kural B; Orem A; Cimşit G; Yandi YE; Calapoglu M
Clin Chim Acta; 2003 Feb; 328(1-2):71-82. PubMed ID: 12559600
[TBL] [Abstract][Full Text] [Related]
5. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease.
Orem A; Cimşit G; Değer O; Vanizor B; Karahan SC
Dermatology; 1999; 198(3):243-6. PubMed ID: 10393445
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies against oxidized LDL and serum total antioxidant status in active cyclists and ex-cyclists.
García-Unzueta MT; Gutiérrez-Sánchez JB; de Mier I; Amado JA; Berrazueta JR
Horm Metab Res; 2003 Sep; 35(9):541-5. PubMed ID: 14517771
[TBL] [Abstract][Full Text] [Related]
7. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients.
Vanizor Kural B; Orem A; Cimşit G; Uydu HA; Yandi YE; Alver A
Clin Chim Acta; 2003 Jun; 332(1-2):23-30. PubMed ID: 12763276
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM.
Bellomo G; Maggi E; Poli M; Agosta FG; Bollati P; Finardi G
Diabetes; 1995 Jan; 44(1):60-6. PubMed ID: 7813815
[TBL] [Abstract][Full Text] [Related]
9. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus.
Uusitupa MI; Niskanen L; Luoma J; Vilja P; Mercuri M; Rauramaa R; Ylä-Herttuala S
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1236-42. PubMed ID: 8857919
[TBL] [Abstract][Full Text] [Related]
11. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease.
Faviou E; Vourli G; Nounopoulos C; Zachari A; Dionyssiou-Asteriou A
Free Radic Res; 2005 Apr; 39(4):419-29. PubMed ID: 16028367
[TBL] [Abstract][Full Text] [Related]
12. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD
Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649
[TBL] [Abstract][Full Text] [Related]
13. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
Turk Z; Mrzljak V; Turk N; Metelko Z
Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
Cvetkovic JT; Wållberg-Jonsson S; Ahmed E; Rantapää-Dahlqvist S; Lefvert AK
Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
[TBL] [Abstract][Full Text] [Related]
15. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL.
Bergmark C; Wu R; de Faire U; Lefvert AK; Swedenborg J
Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):441-5. PubMed ID: 7749854
[TBL] [Abstract][Full Text] [Related]
16. Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation.
Seccia M; Albano E; Maggi E; Bellomo G
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):134-40. PubMed ID: 9012648
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status.
Brizzi P; Tonolo G; Bertrand G; Carusillo F; Severino C; Maioli M; Malaguarnera L; Musumeci S
Clin Chem Lab Med; 2004 Feb; 42(2):164-70. PubMed ID: 15061355
[TBL] [Abstract][Full Text] [Related]
18. Relationship between the sialic acid content of low-density lipoprotein (LDL) and autoantibodies to oxidized LDL in the plasma of healthy subjects and patients with atherosclerosis.
Cerne D; Jürgens G; Ledinski G; Kager G; Greilberger J; Lukac-Bajalo J
Clin Chem Lab Med; 2002 Jan; 40(1):15-20. PubMed ID: 11916265
[TBL] [Abstract][Full Text] [Related]
19. Antibodies against various forms of mildly oxidized low-density lipoprotein are not associated with carotid intima-media thickness in patients with primary hyperlipidemia.
Tsouli SG; Kiortsis DN; Xydis V; Argyropoulou MI; Elisaf M; Tselepis AD
Angiology; 2006; 57(5):615-22. PubMed ID: 17067985
[TBL] [Abstract][Full Text] [Related]
20. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins.
Slot MC; Theunissen R; van Paassen P; Damoiseaux JG; Tervaert JW;
Clin Exp Immunol; 2007 Aug; 149(2):257-64. PubMed ID: 17521320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
